Early trial tests immune therapy for rare chest cancer
NCT ID NCT03295227
Summary
This early-stage trial is testing the safety and best dose of pembrolizumab, an immunotherapy drug, for people with advanced thymoma or thymic carcinoma that cannot be removed by surgery. The study aims to see if this treatment, which helps the body's immune system fight cancer, can control these rare cancers. Researchers will enroll about 37 participants to monitor side effects and see if the treatment slows cancer growth.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE THYMIC CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.